ATE304603T1 - Induzierendes alphavirengen- expressionssystem - Google Patents
Induzierendes alphavirengen- expressionssystemInfo
- Publication number
- ATE304603T1 ATE304603T1 AT99909117T AT99909117T ATE304603T1 AT E304603 T1 ATE304603 T1 AT E304603T1 AT 99909117 T AT99909117 T AT 99909117T AT 99909117 T AT99909117 T AT 99909117T AT E304603 T1 ATE304603 T1 AT E304603T1
- Authority
- AT
- Austria
- Prior art keywords
- rna molecules
- gene expression
- untranslated
- inducing
- methods
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 title 1
- 230000014509 gene expression Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 108020004417 Untranslated RNA Proteins 0.000 abstract 3
- 102000039634 Untranslated RNA Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108020004414 DNA Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000014493 regulation of gene expression Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7956298P | 1998-03-27 | 1998-03-27 | |
| PCT/IB1999/000523 WO1999050432A1 (en) | 1998-03-27 | 1999-03-25 | Inducible alphaviral gene expression system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE304603T1 true ATE304603T1 (de) | 2005-09-15 |
Family
ID=22151327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99909117T ATE304603T1 (de) | 1998-03-27 | 1999-03-25 | Induzierendes alphavirengen- expressionssystem |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7005275B2 (de) |
| EP (1) | EP1066395B1 (de) |
| JP (2) | JP2002509729A (de) |
| AT (1) | ATE304603T1 (de) |
| AU (1) | AU757549B2 (de) |
| CA (1) | CA2325564A1 (de) |
| DE (2) | DE69927249T2 (de) |
| IL (1) | IL138615A0 (de) |
| NZ (1) | NZ507195A (de) |
| WO (1) | WO1999050432A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69927249T2 (de) * | 1998-03-27 | 2006-06-29 | Cytos Biotechnology Ag | Induzierendes alphavirengen- expressionssystem |
| CA2336472C (en) * | 1998-07-03 | 2010-08-31 | Dnavec Research Inc. | Negative-sense rna virus vector for nerve cell |
| US7241617B2 (en) * | 1998-07-03 | 2007-07-10 | Dnavec Research, Inc. | Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci |
| WO2000006205A1 (en) * | 1998-07-29 | 2000-02-10 | Invitrogen Corporation | Regulated expression of recombinant proteins using rna viruses |
| AU7938900A (en) * | 1999-10-27 | 2001-05-08 | Cytos Biotechnology Ag | Method for creating divergent populations of nucleic acid molecules and proteins |
| AU1647501A (en) | 1999-12-10 | 2001-06-18 | Cytos Biotechnology Ag | Replicon based activation of endogenous genes |
| AU2001252458A1 (en) | 2000-05-05 | 2001-11-20 | Martin Bachmann | Molecular antigen arrays and vaccines |
| US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| US7045335B2 (en) * | 2001-09-06 | 2006-05-16 | Alphavax, Inc. | Alphavirus replicon vector systems |
| AU2003266301A1 (en) * | 2002-08-22 | 2004-03-11 | Cytos Biotechnology Ag | Inducible alphaviral/orip based gene expression system |
| EP1644508A1 (de) | 2003-07-11 | 2006-04-12 | Cytos Biotechnology AG | Genexpressionssystem |
| US20080096274A1 (en) * | 2006-10-24 | 2008-04-24 | Guangpu Li | Recombinant alphavirus vectors and methods of using same |
| US10392615B2 (en) | 2015-06-26 | 2019-08-27 | The Regents Of The University Of California | Methods for RNA promoter identification |
| US9859156B2 (en) * | 2015-12-30 | 2018-01-02 | Taiwan Semiconductor Manufacturing Co., Ltd. | Interconnection structure with sidewall dielectric protection layer |
| GB201603374D0 (en) | 2016-02-26 | 2016-04-13 | Ucl Business Plc | Packaging cell |
| IL294290A (en) | 2019-12-31 | 2022-08-01 | Elixirgen Therapeutics Inc | Transient temperature-based delivery of nucleic acids and proteins to cells and tissues |
| WO2023034881A1 (en) * | 2021-09-02 | 2023-03-09 | Elixirgen Therapeutics, Inc. | Temperature-controllable, rna immunotherapeutic for cancer |
| CN113846113B (zh) * | 2021-09-09 | 2022-09-13 | 臻赫医药(杭州)有限公司 | 一种有限自我复制mRNA分子系统、制备方法及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US5091309A (en) * | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| US5217879A (en) * | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
| US5458878A (en) | 1990-01-02 | 1995-10-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity |
| AU6172194A (en) | 1993-02-08 | 1994-08-29 | Paravax, Inc. | Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens |
| CA2158937C (en) | 1993-09-15 | 2006-01-03 | Thomas W. Dubensky, Jr. | Recombinant alphavirus vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US5532154A (en) | 1994-03-21 | 1996-07-02 | Research Development Foundation | Mutated alpha virus |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| EP0907746B1 (de) | 1996-04-05 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US5811407A (en) * | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
| DE69927249T2 (de) * | 1998-03-27 | 2006-06-29 | Cytos Biotechnology Ag | Induzierendes alphavirengen- expressionssystem |
-
1999
- 1999-03-25 DE DE69927249T patent/DE69927249T2/de not_active Expired - Lifetime
- 1999-03-25 IL IL13861599A patent/IL138615A0/xx unknown
- 1999-03-25 JP JP2000541320A patent/JP2002509729A/ja active Pending
- 1999-03-25 DE DE1066395T patent/DE1066395T1/de active Pending
- 1999-03-25 WO PCT/IB1999/000523 patent/WO1999050432A1/en active IP Right Grant
- 1999-03-25 NZ NZ507195A patent/NZ507195A/en unknown
- 1999-03-25 EP EP99909117A patent/EP1066395B1/de not_active Expired - Lifetime
- 1999-03-25 US US09/275,883 patent/US7005275B2/en not_active Expired - Fee Related
- 1999-03-25 AT AT99909117T patent/ATE304603T1/de not_active IP Right Cessation
- 1999-03-25 AU AU28481/99A patent/AU757549B2/en not_active Ceased
- 1999-03-25 CA CA002325564A patent/CA2325564A1/en not_active Abandoned
-
2005
- 2005-07-11 US US11/177,504 patent/US20060024788A1/en not_active Abandoned
- 2005-08-11 JP JP2005233751A patent/JP2005323620A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ507195A (en) | 2003-07-25 |
| IL138615A0 (en) | 2001-10-31 |
| AU757549B2 (en) | 2003-02-27 |
| EP1066395B1 (de) | 2005-09-14 |
| JP2002509729A (ja) | 2002-04-02 |
| US7005275B2 (en) | 2006-02-28 |
| DE69927249D1 (de) | 2005-10-20 |
| US20030053988A1 (en) | 2003-03-20 |
| US20060024788A1 (en) | 2006-02-02 |
| CA2325564A1 (en) | 1999-10-07 |
| AU2848199A (en) | 1999-10-18 |
| JP2005323620A (ja) | 2005-11-24 |
| WO1999050432A1 (en) | 1999-10-07 |
| EP1066395A1 (de) | 2001-01-10 |
| DE1066395T1 (de) | 2002-04-04 |
| DE69927249T2 (de) | 2006-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE304603T1 (de) | Induzierendes alphavirengen- expressionssystem | |
| Zeng et al. | Leveraging mRNA sequences and nanoparticles to deliver SARS‐CoV‐2 antigens in vivo | |
| Morrison | Site of synthesis of membrane and nonmembrane proteins of vesicular stomatitis virus. | |
| Kerekatte et al. | Cleavage of Poly (A)-binding protein by coxsackievirus 2A protease in vitro and in vivo: another mechanism for host protein synthesis shutoff? | |
| Paterson et al. | Efficient translation of prokaryotic mRNAs in a eukaryotic cell-free system requires addition of a cap structure | |
| JP6284181B2 (ja) | 環状ｒｎａ及びタンパク質の製造方法 | |
| Bonatti et al. | Absence of a cleavable signal sequence in Sindbis virus glycoprotein PE2. | |
| BR0007414A (pt) | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc | |
| BR0010725A (pt) | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc | |
| FI932678A (fi) | Pao alfavirus baserande dna expressionssystem | |
| NO20064059L (no) | Albumin fusjonsproteiner | |
| DE69942459D1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
| Nass | Modified nucleosides and cancer | |
| HUP9800329A2 (hu) | Nukleinsavkonstrukciók strukturális gének sejtciklus-függő módon szabályozott expresszálására | |
| EP0232523A3 (en) | Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins | |
| ATE358135T1 (de) | Phagen-abhängige superproduktion biologisch aktiver proteine und peptide | |
| Mruk et al. | Sertolin is a novel gene marker of cell-cell interactions in the rat testis | |
| HUP0302481A2 (hu) | Virulencia gének, fehérjék és alkalmazásuk | |
| ATE310085T1 (de) | Cyclin-e2 proteine und dafür kodierende gene | |
| Carlson et al. | 1-Methylguanosine in place of Y base at position 37 in phenylalanine tRNA is responsible for its shiftiness in retroviral ribosomal frameshifting | |
| Cressey et al. | Distinctive features of the respiratory syncytial virus priming loop compared to other non-segmented negative strand RNA viruses | |
| CO5650177A2 (es) | Constructos geneticos y composiciones que comprenden rre y cte y usos de estos | |
| HUP0304053A2 (hu) | Új expressziós vektorok és azok alkalmazása | |
| Perenkov et al. | In vitro transcribed RNA-based platform vaccines: past, present, and future | |
| DE69529750D1 (de) | Verbesserungen in der herstellung von proteinen in wirtszellen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1066395 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |